BYSI BeyondSpring drug, plinabulin, increased overall survival and improved other measures of disease while staving off a dangerous side effect associated with Chemotherapy.
BeyondSpring is preparing to ask for plinabulin approval in the U.S. and China.
On 8/4/2021 J. Pantginis from HC Wainwright brokerage Upgraded BYSI BeyondSpring from Neutral to Buy giving...
Follow me and smash that like button! Bio-pharmaceutical company aims to treat cancer and genetic diseases. Not the investment. Please do your own due diligence.
Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company.
As of...
